Priliximab
Priliximab is a monoclonal antibody designed for the treatment of cancer. It is a type of biopharmaceutical that is developed through biotechnology processes. Priliximab is one of the many therapeutic antibodies that have been developed to target specific cells in the body, in this case, cancer cells.
History[edit]
The development of Priliximab is part of the broader history of monoclonal antibody therapy, which began in the 1970s with the discovery of the ability to create monoclonal antibodies in the laboratory. This discovery led to the development of a new class of drugs that could target specific cells in the body, opening up new possibilities for the treatment of diseases like cancer.
Mechanism of Action[edit]
Priliximab works by binding to a specific protein on the surface of cancer cells. This binding triggers a series of events that lead to the destruction of the cancer cell. The exact mechanism of action of Priliximab is still under investigation, but it is believed to involve the activation of the body's immune system to attack the cancer cells.
Clinical Trials[edit]
Priliximab has been tested in several clinical trials to evaluate its safety and efficacy in the treatment of various types of cancer. These trials are a crucial part of the drug development process, providing the evidence needed to gain regulatory approval for the use of the drug in patients.
Side Effects[edit]
Like all drugs, Priliximab can cause side effects. These can range from mild reactions, such as rash or fever, to more serious complications, such as infection or organ damage. The risk of side effects must be weighed against the potential benefits of the drug in the treatment of cancer.
Future Directions[edit]
The development of Priliximab and other monoclonal antibodies represents a significant advance in the treatment of cancer. However, much work remains to be done to fully understand the potential of these drugs and to optimize their use in patients. Future research will likely focus on improving the efficacy of Priliximab, reducing its side effects, and exploring its use in combination with other treatments.
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian